Device for deactivating sweat glands
Candesant is a privately-held company dedicated to developing novel solutions for excessive sweating and hyperhidrosis. Candesant’s initial product, CDX-01, is is meant to be a simple, elegant device that offers significant sweat reduction without the pain and tradeoffs of existing therapies.
Founded by Niquette Hunt and Dr. Jacob Waugh, the company most recently posted safety and efficacy data for CDX-101, a non-invasive energy device.
“We are inspired to be able to help the millions of individuals who sweat too much by developing a novel medical device to alleviate their suffering with no downtime,” Hunt, who also serves as CEO, said in a statement to MDO. “Our team of scientists has created an elegantly simple technology that results in an immediate effect, inactivating the most active ducts and sweat glands in the area treated. We are moving through the development process and look forward to bringing this groundbreaking technology to market in late 2021.”
Jacob Wough, Candesant Biomedical’s co-founder and chief scientific officer, said the company technology is intentionally simple in its design.
“ The mechanism of action is literally based upon elemental chemistry,” Wough said. “Sodium reacts to individual molecules of water proportionate to the amount of water or sweat present. This essentially means that we can generate heat where glands are sweating the most to deactivate them. The easy to apply patch progressively heats as a patient is sweating, reaching comparable temperatures to hot tubs.